Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat

• DOI: 10.2337/diab.46.9.1393
• Publication Date: 2013-09-19T17:42:54Z
• Authors: Sophie Haliakon; Liliane Doaré; Fabienne Foufelle; Micheline Kergoat; Michèle Guerre-Millo; Marie-France Bert...; Isabelle Dugail; Joëlle Morin; Johan Auwerx; Pascal Ferré
• Keywords: Pioglitazone; Thiazolidinedione; Carbohydrate Metabolism

Thiazolidinediones are potent antidiabetic compounds, in both animal and human models, which act by enhancing peripheral sensitivity to insulin. high-affinity ligands for peroxisome proliferator-activated receptor-γ, a key factor adipocyte differentiation, they efficient promoters of differentiation vitro. Thus, it could be questioned whether thiazolidinedione therapy aimed at improving insulin would promote the recruitment new adipocytes vivo. To address this problem, we have studied vivo effect pioglitazone on glucose metabolism gene expression adipose tissue an model obesity with resistance, obese Zucker (fa/fa) rat. Pioglitazone markedly improves action rat, but doubles its weight gain after 4 weeks treatment. The drug induces large increase utilization tissue, where stimulates genes involved lipid such as insulin-responsive GLUT, fatty acid synthase, phospho-enolpyruvate carboxykinase genes, decreases ob gene. These changes related enhanced shown number small retroperitoneal fat pad, direct specific (phosphoenolpyruvate genes) mature adipocytes.